Cytiva_APR21_EarlyProcessDevDecisions - 36

Cell and Gene Therapy Sector Needs to Automate

Wladimir Bulgar / Science Photo Library / Getty Images

A focus on data and greater interconnectivity

increase to rely less on manual operations and

in manufacturing is something other cell and

move towards automation, " he explains " This

gene therapy firms should consider.

is not only for process, where most people

" The cell and gene therapy industry is not

concentrate efforts, but also on testing and all

quite ready for advanced manufacturing systems

other manufacturing associated functions to

such as AI. We are really at the point of product

include quality assurance, supply chain and

understanding and transferring processes from

storage. Therefore, not only is there a need for

manual to semi-automated systems, " he says. " The

process automation with companies like Ori

next phase after that would be full automation,

Biotech, but also in-line sensing for analytics

and then on to AI and other advanced technolo-

such as those Sartorius is working on, as well

gies to make critical process decisions based on

as electronic systems like LIMS, MES, and Enter-

manufacturing data. "

prise Resource Planning to help bring every-

This view is shared by David Smith, PhD,
HCATS' R&D director.
" There is a growing need as the volumes

36 |

GENengnews.com

thing together without the need for unreliable
physical human input. "
Automation has applications across the whole


http://www.GENengnews.com

Cytiva_APR21_EarlyProcessDevDecisions

Table of Contents for the Digital Edition of Cytiva_APR21_EarlyProcessDevDecisions

Contents
Cytiva_APR21_EarlyProcessDevDecisions - Cover1
Cytiva_APR21_EarlyProcessDevDecisions - Cover2
Cytiva_APR21_EarlyProcessDevDecisions - Contents
Cytiva_APR21_EarlyProcessDevDecisions - 4
Cytiva_APR21_EarlyProcessDevDecisions - 5
Cytiva_APR21_EarlyProcessDevDecisions - 6
Cytiva_APR21_EarlyProcessDevDecisions - 7
Cytiva_APR21_EarlyProcessDevDecisions - 8
Cytiva_APR21_EarlyProcessDevDecisions - 9
Cytiva_APR21_EarlyProcessDevDecisions - 10
Cytiva_APR21_EarlyProcessDevDecisions - 11
Cytiva_APR21_EarlyProcessDevDecisions - 12
Cytiva_APR21_EarlyProcessDevDecisions - 13
Cytiva_APR21_EarlyProcessDevDecisions - 14
Cytiva_APR21_EarlyProcessDevDecisions - 15
Cytiva_APR21_EarlyProcessDevDecisions - 16
Cytiva_APR21_EarlyProcessDevDecisions - 17
Cytiva_APR21_EarlyProcessDevDecisions - 18
Cytiva_APR21_EarlyProcessDevDecisions - 19
Cytiva_APR21_EarlyProcessDevDecisions - 20
Cytiva_APR21_EarlyProcessDevDecisions - 21
Cytiva_APR21_EarlyProcessDevDecisions - 22
Cytiva_APR21_EarlyProcessDevDecisions - 23
Cytiva_APR21_EarlyProcessDevDecisions - 24
Cytiva_APR21_EarlyProcessDevDecisions - 25
Cytiva_APR21_EarlyProcessDevDecisions - 26
Cytiva_APR21_EarlyProcessDevDecisions - 27
Cytiva_APR21_EarlyProcessDevDecisions - 28
Cytiva_APR21_EarlyProcessDevDecisions - 29
Cytiva_APR21_EarlyProcessDevDecisions - 30
Cytiva_APR21_EarlyProcessDevDecisions - 31
Cytiva_APR21_EarlyProcessDevDecisions - 32
Cytiva_APR21_EarlyProcessDevDecisions - 33
Cytiva_APR21_EarlyProcessDevDecisions - 34
Cytiva_APR21_EarlyProcessDevDecisions - 35
Cytiva_APR21_EarlyProcessDevDecisions - 36
Cytiva_APR21_EarlyProcessDevDecisions - Cover3
Cytiva_APR21_EarlyProcessDevDecisions - Cover4
https://www.nxtbookmedia.com